| Schedule of basic and diluted net loss per share |
Schedule
of basic and diluted net loss per share
| | |
For
the six months ended June 30, | |
| | |
2026 | | |
2025 | |
| Loss attributable
to ordinary equity holders of the parent (TSEK) | |
| (1,118,055 | ) | |
| (887,444 | ) |
| Weighted
average number for ordinary shares for basic and diluted loss per share | |
| 62,629,420 | | |
| 40,677,840 | |
| Basic and diluted loss per
share | |
| (17.85 | ) | |
| (21.82 | ) |
|
The
following table provides the amounts used in the calculation of basic and diluted net loss per share for the years ended December 31,
2025 and 2024:
Schedule
of basic and diluted net loss per share
| | |
For the
year ended
December 31, | |
| (SEK in thousands) | |
2025 | | |
2024 | |
| Loss attributable to shareholders | |
| (1,721,676 | ) | |
| (967,611 | ) |
| Weighted average number of common shares for basic and diluted loss per share | |
| 43,483,470 | | |
| 40,666,082 | |
| Basic and diluted net loss per share | |
| (39.59 | ) | |
| (23.79 | ) |
|
| Schedule of antidilutive shares |
|
The
following table presents the maximum number of shares during the period that were not included in the calculation of diluted loss per
share as their effects would have been antidilutive for the years ended December 31, 2025 and 2024.
Schedule
of antidilutive shares
| | |
| |
2024 | |
| | |
For the
year ended December 31, | |
| | |
2025 | | |
2024 | |
| Employee share options | |
| 1,419,355 | | |
| 1,153,020 | |
| Series A preference shares | |
| 20,762,302 | | |
| 20,762,302 | |
| Series B preference shares | |
| 24,173,854 | | |
| 24,173,854 | |
| Series C preference shares | |
| 23,438,522 | | |
| 15,135,490 | |
| Convertible debenture | |
| - | | |
| - | |
| Employee share purchase warrants | |
| 16,351,965 | | |
| 9,470,134 | |
| Non-employee share purchase warrants | |
| 6,854,065 | | |
| 6,854,065 | |
| Total antidilutive shares | |
| 93,000,063 | | |
| 77,548,865 | |
|